Literature DB >> 9435559

IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes.

J K Linevsky1, C Pothoulakis, S Keates, M Warny, A C Keates, J T Lamont, C P Kelly.   

Abstract

Neutrophil infiltration is central to the pathogenesis of Clostridium difficile toxin A-induced enterocolitis. This study examines whether monocyte activation by C. difficile toxins is instrumental in initiating neutrophil activation and recruitment. Human monocytes were exposed to low concentrations of highly purified C. difficile toxins, and the conditioned media were harvested for cytokine and functional assays. Monocytes exposed to C. difficile toxin A (10(-10) M) or toxin B (10(-12) M) released 100 and 20 times basal levels, respectively, of the neutrophil chemoattractant interleukin-8 (IL-8). Reverse transcriptase-polymerase chain reaction demonstrated a marked increase in IL-8 mRNA expression by monocytes 3 h after toxin exposure. Conditioned media from toxin A- and toxin B-treated monocytes stimulated neutrophil migration (324 and 245% of control, respectively). This effect was completely blocked by IL-8 antiserum. These media also upregulated neutrophil CD11b/CD18 and endothelial cell intercellular adhesion molecule-1 expression. C. difficile toxins, at low concentrations, potently activate monocytes to release factors, including IL-8, that facilitate neutrophil extravasation and tissue infiltration. Our findings indicate a major role for toxin-mediated monocyte and macrophage activation in C. difficile colitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9435559     DOI: 10.1152/ajpgi.1997.273.6.G1333

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  33 in total

1.  p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis.

Authors:  M Warny; A C Keates; S Keates; I Castagliuolo; J K Zacks; S Aboudola; A Qamar; C Pothoulakis; J T LaMont; C P Kelly
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

3.  Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury.

Authors:  Simon A Hirota; Kyla Fines; Jeffrey Ng; Danya Traboulsi; Josh Lee; Eikichi Ihara; Yan Li; William G Willmore; Daniel Chung; Melanie M Scully; Thomas Louie; Shaun Medlicott; Manigandan Lejeune; Kris Chadee; Glen Armstrong; Sean P Colgan; Daniel A Muruve; Justin A MacDonald; Paul L Beck
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 4.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

5.  Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.

Authors:  I Castagliuolo; M F Riegler; L Valenick; J T LaMont; C Pothoulakis
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

6.  TPL2 Is a Key Regulator of Intestinal Inflammation in Clostridium difficile Infection.

Authors:  Yuanguo Wang; Shaohui Wang; Ciaran P Kelly; Hanping Feng; Andrew Greenberg; Xingmin Sun
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

7.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

8.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

9.  Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases.

Authors:  Dezheng Zhao; Sabina Kuhnt-Moore; Huiyan Zeng; Amy Pan; Jack S Wu; Simos Simeonidis; Mary P Moyer; Charalabos Pothoulakis
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

10.  Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered.

Authors:  Munir M Zaman; Andres Gelrud; Omer Junaidi; Meredith M Regan; Michel Warny; Julie C Shea; Ciaran Kelly; Brian P O'Sullivan; Steven D Freedman
Journal:  Clin Diagn Lab Immunol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.